31 related articles for article (PubMed ID: 38362631)
1. [Primary hepatic sarcomatoid carcinoma, an unusual case].
Rueda DA; Antinucci F; Amante MF; Bas CA
Medicina (B Aires); 2024; 84(2):337-341. PubMed ID: 38683520
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review.
Wang L; Huang Y; Sun X
Front Oncol; 2024; 14():1362160. PubMed ID: 38725630
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis.
Salati M; Baldessari C; Calabrese F; Rossi G; Pettorelli E; Grizzi G; Dominici M; Barbieri F
Case Rep Oncol; 2018; 11(3):615-621. PubMed ID: 30323751
[TBL] [Abstract][Full Text] [Related]
4. Transdiaphragmatic sarcomatoid carcinoma of the lung: A case report.
Hutchings H; Theisen B; Cox J; Okereke I
Int J Surg Case Rep; 2024 Apr; 119():109675. PubMed ID: 38718493
[TBL] [Abstract][Full Text] [Related]
5. enHanCCing knowledge of genetic factors in primary liver tumor.
Koshiol J; Krawczyk M
Hepatology; 2024 Feb; ():. PubMed ID: 38349672
[No Abstract] [Full Text] [Related]
6. A history of the treatment of primary liver cancer.
Bruix J
Clin Liver Dis (Hoboken); 2024; 23(1):e0147. PubMed ID: 38707239
[No Abstract] [Full Text] [Related]
7. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases.
Whaley RD; Cheng L
Am J Surg Pathol; 2022 Sep; 46(9):1171-1179. PubMed ID: 35687360
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.
Yoshuantari N; Jeng YM; Liau JY; Lee CH; Tsai JH
Mod Pathol; 2023 Jan; 36(1):100042. PubMed ID: 36788061
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
11. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
12. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
14. Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
